What is the 13F Pro Quality Score for EDSA?

13F Pro ranks Edesa Biotech, Inc. (EDSA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View EDSA's current score at https://13fpro.ai/company/EDSA (free sign-up required for the full ranking).

Where does 13F Pro source EDSA data?

All Edesa Biotech, Inc. fundamentals and ownership data come directly from SEC EDGAR. Edesa Biotech, Inc. files with the SEC under CIK 1540159. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is EDSA in?

Edesa Biotech, Inc. (EDSA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is EDSA research updated on 13F Pro?

EDSA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Edesa Biotech, Inc.(EDSA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1540159 EDSA stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $1.3M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

EDSA Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for Edesa Biotech, Inc. (EDSA), a Healthcare sector company. EDSA is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $1.3m in revenue and is scored on the micro-cap board instead. Top institutional holders of EDSA by reported 13-F value include Velan Capital Investment Management, Rubric Capital Management, PERCEPTIVE ADVISORS, based on the most recent SEC filings. EDSA trades on the Nasdaq exchange and files with the SEC under CIK 1540159. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate EDSA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Edesa Biotech, Inc. directly from SEC EDGAR.

✦

Fun facts about Edesa Biotech, Inc.

Quirks, history, and lore behind EDSA — the kind of stuff that makes a stock memorable.

1
The Basics
A clinical-stage biopharmaceutical company · listed on Nasdaq · headquartered in Canada · focused on inflammatory and immune-related diseases.
2
The Numbers
A true micro-cap with minimal revenue — the financials are mostly R&D spend and cash burn, as is typical for a company that hasn't yet brought a product to market.
3
The History
The company was built around assets licensed from larger pharmaceutical players, giving it a pipeline without starting from scratch in the lab.
4
The Secret
Its lead programs target conditions like atopic dermatitis and hemorrhagic shock — a surprisingly wide swing between skin inflammation and emergency trauma care.
5
The Lore
It has explored a topical anti-inflammatory candidate that competes in the same crowded skin-disease space drawing Big Pharma billions — a small fish in a very large pond.
6
The Giveaway
Its four-letter ticker starts with the letters of its name, and its name is a mashup of "edema" and biotech — a literal hint at the swelling conditions it hopes to treat.

▶ Think you know your stocks? Play the Daily Ticker

Net Income

Q2 2026

$-5.4M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

—FY 2025

FY22 $780.0KFY23 —FY24 —FY25 —

Net Income

-16.5% YoY

$-7.2MFY 2025

FY22 $-17.5MFY23 $-8.4MFY24 $-6.2MFY25 $-7.2M

Operating Income

-12.8% YoY

$-7.9MFY 2025

FY22 $-18.4MFY23 $-9.2MFY24 $-7.0MFY25 $-7.9M

Total Assets

+254.8% YoY

$13.5MFY 2025

FY22 $11.6MFY23 $8.9MFY24 $3.8MFY25 $13.5M

Op. Cash Flow

-49.7% YoY

$-7.3MFY 2025

FY22 $-12.3MFY23 $-6.6MFY24 $-4.9MFY25 $-7.3M

Free Cash Flow

—FY 2025

FY22 $-12.3MFY23 $-6.6MFY24 —FY25 —

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	—	—	—	$780.0K	$0.00 -100.0%	$328.8K
Net Income	$-7.2M -16.5%	$-6.2M +26.3%	$-8.4M +52.3%	$-17.5M -31.5%	$-13.3M -109.7%	$-6.4M
Operating Income	$-7.9M -12.8%	$-7.0M +23.9%	$-9.2M +49.8%	$-18.4M +22.4%	$-23.7M -270.0%	$-6.4M
Total Assets	$13.5M +254.8%	$3.8M -57.1%	$8.9M -23.2%	$11.6M -20.6%	$14.6M +35.5%	$10.8M
Operating Cash Flow	$-7.3M -49.7%	$-4.9M +26.3%	$-6.6M +46.0%	$-12.3M +10.1%	$-13.7M -174.0%	$-5.0M
Free Cash Flow	—	—	$-6.6M +46.0%	$-12.3M +10.1%	$-13.7M -173.9%	$-5.0M

Get alerted when EDSA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Edesa Biotech, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of EDSA

Velan Capital Investment Management LP
$6.7M827,500 sh
Rubric Capital Management LP
$5.4M669,500 sh
PERCEPTIVE ADVISORS LLC
$4.6M563,239 sh
MILLENNIUM MANAGEMENT LLC
$4.6M561,751 sh
Stonepine Capital Management, LLC
$3.2M456,439 sh
Boxer Capital Management, LLC
$1.7M205,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$665.4K81,839 sh
GEODE CAPITAL MANAGEMENT, LLC
$657.6K80,879 sh
JANE STREET GROUP, LLC
$589.1K72,465 sh
VANGUARD FIDUCIARY TRUST CO
$314.8K38,718 sh

Fund	Value	Shares
Velan Capital Investment Management LP	$6.7M	827,500
Rubric Capital Management LP	$5.4M	669,500
PERCEPTIVE ADVISORS LLC	$4.6M	563,239
MILLENNIUM MANAGEMENT LLC	$4.6M	561,751
Stonepine Capital Management, LLC	$3.2M	456,439
Boxer Capital Management, LLC	$1.7M	205,000
VANGUARD CAPITAL MANAGEMENT LLC	$665.4K	81,839
GEODE CAPITAL MANAGEMENT, LLC	$657.6K	80,879
JANE STREET GROUP, LLC	$589.1K	72,465
VANGUARD FIDUCIARY TRUST CO	$314.8K	38,718

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put EDSA on your watchlist

Track score changes the day Edesa Biotech, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is EDSA a good stock to buy?

13F Pro's AI-powered analysis of Edesa Biotech, Inc. (EDSA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for EDSA are available on the EDSA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. EDSA is classified as a small company.

Which hedge funds own EDSA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling EDSA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Edesa Biotech, Inc.'s investment landscape.